ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

KOOL Cesca Therapeutics Inc

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
Cesca Therapeutics Inc NASDAQ:KOOL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0 -

Cesca Therapeutics To Present At The 2019 Bio Investor Forum

14/10/2019 1:30pm

PR Newswire (US)


Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Cesca Therapeutics Charts.

RANCHO CORDOVA, Calif., Oct. 14, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that Jeff Cauble, Vice President of Finance and Principal Accounting Officer, will present at the 2019 BIO Investor Forum on Tuesday, October 22 at 4:00 pm PT. The Forum is being held October 22-23 at the Westin St. Francis Hotel in San Francisco.

Management will also be available for one-on-one meetings with qualified investors, analysts and interested, potential partners. Those who would like to attend Cesca's presentation or meet with management can register through the BIO Investor Forum website or contact Rx Communications to schedule a meeting.

A live webcast of the presentation will be available on Cesca Therapeutics' website at http://investors.cescatherapeutics.com/events-and-presentations/events.

About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis develops, commercializes and markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company has developed a semi- automated, functionally closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market. For more information about Cesca and ThermoGenesis, please visit: www.cescatherapeutics.com.

Company Contact:
Wendy Samford
916-858-5191
ir@thermogenesis.com

Investor Contact:
Paula Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com

Cision View original content:http://www.prnewswire.com/news-releases/cesca-therapeutics-to-present-at-the-2019-bio-investor-forum-300937645.html

SOURCE Cesca Therapeutics Inc.

Copyright 2019 PR Newswire

1 Year Cesca Therapeutics Chart

1 Year Cesca Therapeutics Chart

1 Month Cesca Therapeutics Chart

1 Month Cesca Therapeutics Chart